Product Name: Human CEACAM5 / CEA / CD66e Antibody (CergutuzumAb, Research Use)
Catalog Number: NBR-0598
Target Name: CEACAM5 / CEA / CD66e
Trade Name: CergutuzumAb
Antibody Drug Description: Cergutuzumab amunaleukin is a novel monomeric CEA-targeted immunocytokine, that comprises a single IL-2 variant (IL2v) moiety with abolished CD25 binding, fused to the C-terminus of a high affinity, bivalent carcinoembryonic antigen (CEA)-specific antibody devoid of Fc-mediated effector functions. Appearance: Transparent Liquid
Molecular Weight: ~150kDa
CAS：N/A
Solubility: Water; PBS, TBS Buffer etc.
Expression System: CHO Expressed
Isotype of Ab: Ab. Isotype - IgG

  Gene Name: CD66e
Synonyms: CD66e; CEA
Target Description: CEACAM5 (CEA Cell Adhesion Molecule 5) is a Protein Coding gene. Diseases associated with CEACAM5 include Bile Duct Cancer and Lung Cancer. Among its related pathways are Metabolism of proteins and Response to elevated platelet cytosolic Ca2+. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and GPI anchor binding. An important paralog of this gene is CEACAM1.
Ensembl:  ENSG00000105388
Uniprot: P06731